Articles related to CLINICAL TRIALS

In a phase 3 trial, tisotumab vedotin showed a median overall survival of 11.5 months compared to 9.5 months with standard chemotherapy in patients with recurrent cervical cancer, representing a 30% reduction in the risk of death.

Dupilumab significantly induced histologic remission in 68% of children with eosinophilic esophagitis compared to 3% in the placebo group, according to a phase 3 trial.

This study reveals that individuals with autosomal dominant Alzheimer’s disease who are heterozygous for the APOE3 Christchurch variant experience a median delay in cognitive impairment onset of approximately five years compared to those without the variant.

In a Chinese study, tenecteplase administered 4.5 to 24 hours after stroke onset resulted in less disability at 90 days compared to standard treatment, though it carried a higher risk of symptomatic intracranial hemorrhage.

In a randomized trial of 1,412 patients with acute ischemic stroke, reteplase was more likely to result in excellent functional outcomes at 90 days compared to alteplase.

Many modern oncology trials prioritize drug approval over patient welfare, often using inferior control arms that do not reflect the best available treatment.